<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/87F00872-DE4E-44C4-8149-C1ECF5B368BD"><gtr:id>87F00872-DE4E-44C4-8149-C1ECF5B368BD</gtr:id><gtr:name>The Walton Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0B638AA-F9B3-48E6-A841-17B44A6152C9"><gtr:id>C0B638AA-F9B3-48E6-A841-17B44A6152C9</gtr:id><gtr:name>University of Portsmouth</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>CRUK/MRC Oxford Inst for Radiation Oncol</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/87F00872-DE4E-44C4-8149-C1ECF5B368BD"><gtr:id>87F00872-DE4E-44C4-8149-C1ECF5B368BD</gtr:id><gtr:name>The Walton Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0B638AA-F9B3-48E6-A841-17B44A6152C9"><gtr:id>C0B638AA-F9B3-48E6-A841-17B44A6152C9</gtr:id><gtr:name>University of Portsmouth</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EF20884F-1419-4BC5-BFAB-70530EBA02D5"><gtr:id>EF20884F-1419-4BC5-BFAB-70530EBA02D5</gtr:id><gtr:firstName>Benjamin</gtr:firstName><gtr:surname>Davis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0A3CB14D-AEB9-4CFF-ACD1-718D81C84412"><gtr:id>0A3CB14D-AEB9-4CFF-ACD1-718D81C84412</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Gareth</gtr:otherNames><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DE32C476-09A8-4BCA-A101-9312BFB03827"><gtr:id>DE32C476-09A8-4BCA-A101-9312BFB03827</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:otherNames>Clive</gtr:otherNames><gtr:surname>Anthony</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3E5976A0-A73A-48DA-8DFD-A02C982BDEFA"><gtr:id>3E5976A0-A73A-48DA-8DFD-A02C982BDEFA</gtr:id><gtr:firstName>Nicola</gtr:firstName><gtr:otherNames>Ruth</gtr:otherNames><gtr:surname>Sibson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/75704C12-1732-4A49-9184-6D4E81C96D36"><gtr:id>75704C12-1732-4A49-9184-6D4E81C96D36</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:surname>Choudhury</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B945B40C-1E37-478C-9FB5-9EF3F91D1417"><gtr:id>B945B40C-1E37-478C-9FB5-9EF3F91D1417</gtr:id><gtr:firstName>Ruth</gtr:firstName><gtr:otherNames>Josephine</gtr:otherNames><gtr:surname>Muschel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902181"><gtr:id>9E4E86AA-B194-4563-B834-2499C0F28298</gtr:id><gtr:title>Novel targeted contrast agent for early detection of brain metastasis: from animal to patient</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902181</gtr:grantReference><gtr:abstractText>Metastasis is the spread of cancer from the initial site, e.g. breast or lung, to another part of the body. Metastasis to the brain is one of the most feared complications of cancers such as breast and lung, as they cannot be detected at a stage when they can be treated and life expectancy once diagnosed is generally only a few months. Magnetic resonance imaging (MRI) is widely used for diagnosing brain cancer, but the techniques are only sensitive to tumours that are large and well advanced. These MRI methods use so-called contrast agents, which can be thought of as dyes that alter the colour or intensity of the images in the areas where they are present. Until now the contrast agents used in cancer diagnosis have been passive in that they require major damage to the brain blood vessels to allow their passive accumulation within the tumour. As a result, treatments that might have been successful at earlier stages do not work, because the disease is too far advanced. To overcome this problem, we have been developing a new type of MRI contrast agents that will actively bind to specific molecules associated with disease, and identify areas where levels of these molecules are increased. We have found that the levels of certain molecules on the blood vessels in the brain are increased early in the development of brain disease. In particular, we have identified specific molecules that are increased in the early stages of brain metastasis. By designing contrast agents that will bind to these specific molecules, we believe that we have found a way of detecting early brain metastasis when it cannot otherwise be seen. We have already shown that our targeted contrast agent works in mouse models of brain metastasis. The first aim of this project, therefore, is to take our agent and convert it to a form that will work in humans. We will then test this humanised form of the agent both for detection of the target human molecule and for any potentially harmful or toxic effects. When we have completed the work in this proposal, the humanised contrast agent will be taken forward into a clinical trial. We believe that our approach will greatly improve our ability to diagnose brain metastases in the early stages and, as a result, change the way in which patients with this currently incurable disease are treated and managed.</gtr:abstractText><gtr:technicalSummary>Metastatic spread of a primary tumour to the brain remains one of the greatest hurdles in cancer therapy, and prognosis is poor. Magnetic resonance imaging (MRI) is commonly used for the diagnosis of brain cancer, but current, gadolinium-enhanced techniques are sensitive only to larger, late stage tumours ( 5mm), when therapeutic potential is limited. Our approach, capable of detecting 200um tumours, will enable much earlier detection of brain metastases. We have developed targeted MRI contrast agents, which detect specific molecules expressed early in disease. We have shown that our new patent-protected contrast agent, targeting the endovascular adhesion molecule VCAM-1, enables early detection of metastases in mouse brain when they are undetectable by existing clinically-used methods. Importantly, we have also demonstrated expression of VCAM-1 in human post-mortem brain tissue containing micrometastases. We believe that early diagnosis of brain metastases using our contrast agent will increase therapeutic options and change clinical management of a substantial number of cancer patients. Our aim here is to fully humanise the targeting anti-VCAM-1 antibody and to take the humanised contrast agent through preclinical and toxicological testing, prior to clinical trials. Our approach has already generated considerable interest amongst both Oncologists and Imaging Companies.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-16</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>748233</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>VCAM-targeted MRI in neurological disease</gtr:description><gtr:id>F7EE2CB6-21BF-401F-AEB1-09EA031920A5</gtr:id><gtr:impact>None yet
Multi-disciplinary - biology, physics/imaging, chemistry</gtr:impact><gtr:outcomeId>5786343807d492.70424578-1</gtr:outcomeId><gtr:partnerContribution>Applying the VCAM-MPIO in models of dementia.</gtr:partnerContribution><gtr:piContribution>Provision of VCAM-MPIO contrast agent and SOPs for synthesis and use in animal models.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Portsmouth</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Imaging CAM expression in brain tumours</gtr:description><gtr:id>22687D1C-449C-440D-8F35-D4589187BE7C</gtr:id><gtr:impact>None yet.
Multi-disciplinary - biology, physics/imaging</gtr:impact><gtr:outcomeId>578633c710d144.29413425-1</gtr:outcomeId><gtr:partnerContribution>Provision of knockdown tumour cell lines</gtr:partnerContribution><gtr:piContribution>Development of models with knockdown tumour cell lines from Portsmouth and imaging of these with our molecular MRI contrast agents.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Image guided brain metastasis study</gtr:description><gtr:id>B0D25761-063B-40B8-BACA-6EC49ECE11B6</gtr:id><gtr:impact>Manuscript currently in revision for Oncotarget.</gtr:impact><gtr:outcomeId>56deb986300fb2.98039539-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators at The Walton Centre have provided imaging data and biopsy samples.</gtr:partnerContribution><gtr:piContribution>We have assessed inflammatory signatures in samples from the invasive edges of brain metastases in patients identified by image guidance at The Walton Centre.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford Cancer Research Center Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A8181AAA-178C-4346-8809-88E1294C1438</gtr:id><gtr:impact>60 school children attended the open day at which we had a stand describing our work in taking our VCAM-targeted MRI contrast agent to clinical trial.

Feedback indicated a high degree of interest and enthusiasm for the science, with several children inspired to consider science as a career.</gtr:impact><gtr:outcomeId>YZ7tUessNtT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>170E4329-5C8B-4C32-9AC7-5A77A7A55729</gtr:id><gtr:impact>A description of our research and short exerts from the interview were broadcast on several news bulletins throughout the morning on BBC Radio Oxford and Jack FM.

A member of the public contacted us afterwards to ask if our treatment was ready for use, as his wife was suffering from brain tumours.</gtr:impact><gtr:outcomeId>pc7LavZAs53</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Cancer Research Center Open Evening</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E357AC54-A378-4241-B5D9-6159FFD56AFB</gtr:id><gtr:impact>100 members of the public, including cancer patients and CR-UK supporters, attended the open day at which we had a stand describing our work in taking our VCAM-targeted MRI contrast agent to clinical trial.

Feedback indicated a high degree of interest and enthusiasm for the technology and advance in cancer diagnosis presented.</gtr:impact><gtr:outcomeId>mT1Zn1kZt1v</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teachers workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ED6EBC84-A475-43EF-8E49-1DDF35F3402E</gtr:id><gtr:impact>Approximately 20 teachers attended the workshop and were provided with various tools for introducing the topic of cancer and brain imaging into their curricular activities.

Further interaction with some of the schools involved, and requests for school visits.</gtr:impact><gtr:outcomeId>5457a811471b18.72649650</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Lab Tour Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7563AE6F-C80E-423E-BD9D-EAB83209FF65</gtr:id><gtr:impact>Several Corporate funders and research nurses attended the visit, and were very interested to learn about our current research into brain metastasis and how we hope to move this into the clinic shortly.

I was contacted afterwards by one of the research nurses describing their interest in our work.</gtr:impact><gtr:outcomeId>5457a791922fb0.23644892</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MSc and DTC Lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>83C545AF-D8F2-4512-A31F-101DC21E5B48</gtr:id><gtr:impact>Regular lectures on brain imaging in cancer and neurosciences to Doctoral Training Course and M.Sc. students, which sparked questions and discussion as well as interest in entering research within this field of research. Outcome is often one or more students joining the group for either M.Sc. or D.Phil. projects.

Development of collaborations and numerous examples of interest in applying our VCAM-targeted technology in different patients groups from paediatrics to head injury.</gtr:impact><gtr:outcomeId>T9JFKsp4YRH</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>7922968</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Programme Grant</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/L024012/1</gtr:fundingRef><gtr:id>33B66C31-AF9A-4D0D-8068-B0158AAEA4E6</gtr:id><gtr:outcomeId>5457a52adf9644.59109404</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015443/1</gtr:fundingRef><gtr:id>673A437B-EAEF-4A7B-A3CF-1CAF64F9A43D</gtr:id><gtr:outcomeId>56deaf498570e1.03483088</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Development of fully humanised antibody against human VCAM-1 with appropriate properties for targeting molecular imaging agents.</gtr:description><gtr:grantRef>G0902181</gtr:grantRef><gtr:id>C81CBBF6-6689-4C15-ADE1-98CA2FE43ACC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>Ledmf7m9Doh</gtr:outcomeId><gtr:patentId>WO2013160676</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Monoclonal antibody clones to VCAM-1</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Humanised anti-VCAM-1 antibody</gtr:description><gtr:id>D9DAF20F-6278-4C80-96CF-E2FC94235D6E</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>Mk7jkudiWSV</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>VCAM-ab</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>794535BC-CDFD-4796-832D-CCE1C01AC13C</gtr:id><gtr:title>Covalent assembly of nanoparticles as a peptidase-degradable platform for molecular MRI.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e94e76423084d6db3ef575ca8d05e0b"><gtr:id>1e94e76423084d6db3ef575ca8d05e0b</gtr:id><gtr:otherNames>Perez-Balderas F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58a5835608f463.74251228</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902181</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>